Metabolic and Structural Characterization of Hub's Vulnerability in Neurological Diseases Assessed by Ultra High Field Structural and Functional MRI
NCT ID: NCT03039166
Last Updated: 2017-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
260 participants
INTERVENTIONAL
2017-05-31
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective here is to test this hypothesis and provides better understandings on pathophysiological processes affecting those highly connected regions in 'diffuse' and 'focal' neurological diseases.
The ultimate goal is to identify new clinical targets for trans-nosological approaches (DBS, cognitive rehabilitation ...).
Practically, the investigators will explore 200 patients classified in 5 cohorts of 40 patients suffering for MS, AD, Parkinson, ALS, Epilepsy, using the last advanced methods to assess structural and functional brain connectivity implemented on the human 7T MR scanner equipping the CEMEREM (CHU Timone, Marseille, only 50 similar MR scanners worldwide).
In addition to high resolution diffusion MRI and rs-fMRI, metabolic and ionic (sodium) mapping will complement the MR protocol to characterize the pathophysiological processes of hub injury. Sixty healthy controls will also be explored wih the same protocol for normal database.
The proposal aims at characterizing and comparing from a morphological-functional point of view, the hub regions of patients suffering from these five diseases, to demonstrate the pertinence to preserve hub integrity as a major therapeutic target whatever the disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET
NCT02058043
Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI
NCT02522091
Creation of a Probabilistic Atlas of Normal Cerebral Uptake of 18F-FDG in PET/MRI.
NCT05355857
Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease
NCT02605161
Discard the Curative Causes of Late Onset Epilepsy: the Role of Brain 18F-FDG PET
NCT05831371
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
parkinson
MRI 7T
MRI 3 T
partial epilepsy
MRI 7T
MRI 3 T
alzheimer disease
MRI 7T
MRI 3 T
multiple sclerosis
MRI 7T
MRI 3 T
blood sample
amyotrophic lateral sclerosis
MRI 7T
MRI 3 T
healthy control patients
MRI 7T
MRI 3 T
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI 7T
MRI 3 T
blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person presenting unchecked general disease such as severe cancer, autoimmune disease, hepatic insufficiency, severe or untreated, shady arterial high blood pressure of the conduction or the disorder of the rhythm
* Person presenting chronic psychiatric disease, insane syndrome.
* Person presenting contraindication to the realization of an examination by MRI (metallic claustrophobia, foreign body, pacemakers),
* Person benefiting from a social security cover,
* Person having read, understood and signed an informed consent after information
Exclusion Criteria
* Metallic foreign bodies,
* Pacemakers,
* Severe renal insufficiency
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine GEINDRE
Role: STUDY_DIRECTOR
Assistance Publique Hopitaux De Marseille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiatnce Publique Hopitaux de Marseille
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-46
Identifier Type: OTHER
Identifier Source: secondary_id
2016-A01785-46
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.